News|Articles|October 3, 2024

Empower Sponsor Success with Insights from Sites

Author(s)YPrime

Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 11th, 2026

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, shares three priorities for first-time APAC sponsors: aligning with marketing authorization plans, selecting the right sites, and choosing a CRO with regional experience and KOL networks.

How regulatory guidance, blinding, study-provisioned devices, and ePRO integration shape reliable CGM data collection in diabetes clinical trials. Credit: Stock.Adobe.com/martenaba

November 11th, 2026

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

FDA and EMA expectations shape how sponsors use CGM in diabetes trials, from blinding and study-provisioned devices to data integrity and ePRO integration.

November 11th, 2026

ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval

In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.

November 10th, 2026

The Role of Clinical Research Professionals: From Early Discovery to Phase III Success

A pivotal trial that missed its primary endpoint became the basis for a successful redesign after the team used the data to define the high-risk patients most likely to benefit, showing that setbacks can strengthen development when organizations interrogate the evidence rather than abandon it.

November 10th, 2026

What Large Pharma Has Figured Out About APAC That Smaller Biotechs Are Still Learning

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, outlines why faster recruitment, local data requirements for registration, and lower costs make APAC attractive for global Phase III programs.

November 10th, 2026

ACT Brief: China’s Startup Timelines, AI-Drafted Clinical Study Reports, and Bimzelx Psoriatic Arthritis Data

In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.

November 9th, 2026

AI Can Draft the CSR Faster, But Does That Make Drug Development Faster?

AI can draft a CSR in minutes, but the report only reflects evidence that has already converged, so faster drafting shifts the bottleneck to upstream reconciliation, database-lock readiness, and human accountability rather than shortening the trial itself.

November 9th, 2026

How China Cut Its Phase III Startup Timeline and What Drove the Change

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, details how NMPA reforms, parallel reviews, and expanded reviewer capacity brought China’s startup timelines in line with the US and Europe, and could shorten them further.